Literature DB >> 33867297

Effects of 3D image-guided brachytherapy compared to 2D conventional brachytherapy on clinical outcomes in patients with cervical cancer: A systematic review and meta-analyses.

Erica Aranha Suzumura1, Layse Martins Gama2, Beate Jahn3, Alessandro Gonçalves Campolina4, Heloisa de Andrade Carvalho2, Patrícia Coelho de Soárez5.   

Abstract

PURPOSE: To assess the effects of three-dimensional image-guided brachytherapy (3D BT) compared to bi-dimensional BT (2D BT) on clinical outcomes in patients with cervical cancer. METHODS AND MATERIALS: We searched PubMed/MEDLINE, EMBASE, Scopus, CENTRAL, Web of Science, and LILACS for studies assessing the effects of 3D BT versus 2D BT on clinical outcomes. Two reviewers independently screened retrieved citations, extracted data and assessed risk of bias from eligible studies. Hazard ratios (HR) were calculated from Kaplan-Meier curves considering the number of events, their timing and the followup of censored patients. We conducted meta-analyses of HR using the inverse-variance random-effects method. Risk Difference (RD) for toxicities were pooled using the Mantel-Haenszel random-effects method. We used the GRADE system to rate the certainty of evidence.
RESULTS: Twenty observational studies involving 4287 patients were included. The meta-analyses assessing the effect of 3D BT versus 2D BT on overall survival resulted in a HR of 0.78 (95%CI 0.62-0.98), HR of 0.75 (95%CI 0.62-0.90) for pelvic disease-free survival, HR of 0.93 (95%CI 0.81-1.06) for metastatic disease-free survival, and HR of 0.77 (95%CI 0.59-0.99) for local control. Grade 3-4 global and gastrointestinal toxicities were, respectively, 9% lower (95%CI 6% to 11%) and 5% lower (95%CI 2% to 8%) in patients receiving 3D BT versus 2D BT. Certainty of evidence was very low for all assessed outcomes.
CONCLUSIONS: Our study may suggest a benefit of 3D BT over conventional 2D BT on important clinical outcomes.
Copyright © 2021 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brachytherapy; Cervical cancer; GRADE; Meta-analysis; Systematic review; Uterine cervical neoplasms

Year:  2021        PMID: 33867297     DOI: 10.1016/j.brachy.2021.03.004

Source DB:  PubMed          Journal:  Brachytherapy        ISSN: 1538-4721            Impact factor:   2.362


  4 in total

Review 1.  Combined Interstitial and Intracavitary High-Dose Rate Brachytherapy of Cervical Cancer.

Authors:  Jun Itami; Naoya Murakami; Miho Watanabe; Shuhei Sekii; Takahiro Kasamatsu; Shingo Kato; Hisako Hirowatari; Hitoshi Ikushima; Ken Ando; Tatsuya Ohno; Hiroyuki Okamoto; Kae Okuma; Hiroshi Igaki
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

2.  Optimizing the IPSA Conditions to Improve the Treatment Plan Quality in Brachytherapy for Cervical Cancer.

Authors:  Xinglong Yang; Zhouyu Li; Zhantuo Cai; Xi Tang; Jinquan Liu; Shuzhong Cui; Mingyi Li
Journal:  J Oncol       Date:  2022-03-12       Impact factor: 4.375

3.  Brachytherapy dose changes: comparing in-room and out-room image-guided brachytherapy. A randomized study.

Authors:  Pooriwat Muangwong; Ekkasit Tharavichitkul; Patumrat Sripan; Somvilai Chakrabandhu; Pitchayaponne Klunklin; Wimrak Onchan; Bongkot Jia-Mahasap; Razvan Galalae; Imjai Chitapanarux
Journal:  J Contemp Brachytherapy       Date:  2022-08-19

Review 4.  Comparative Analysis of 60Co and 192Ir Sources in High Dose Rate Brachytherapy for Cervical Cancer.

Authors:  Aiping Wen; Xianliang Wang; Bingjie Wang; Chuanjun Yan; Jingyue Luo; Pei Wang; Jie Li
Journal:  Cancers (Basel)       Date:  2022-09-29       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.